TrialRheumatology (Oxford, England)2021

Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus.

Richard A Furie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.